Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Safety and Effectiveness Study of a Fiber Supplement for Weight Loss

This study has been completed.
Information provided by (Responsible Party):
Joyce K Keithley, Rush University Medical Center Identifier:
First received: January 31, 2008
Last updated: December 1, 2011
Last verified: December 2011
Overweight and obesity are serious and growing problems within the United States. The usual approaches to weight loss-dieting, exercise, and behavioral interventions-rarely result in long-term weight loss. Therefore, we will evaluate the safety and efficacy of glucomannan, a fiber supplement that has promising weight loss effects.

Condition Intervention Phase
Dietary Supplement: Glucomannan
Dietary Supplement: Inert microcrystalline cellulose
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Safety and Efficacy of Glucomannan for Weight Loss

Resource links provided by NLM:

Further study details as provided by Rush University Medical Center:

Primary Outcome Measures:
  • Weight loss [ Time Frame: 8 weeks ]

Secondary Outcome Measures:
  • Body composition [ Time Frame: 8 weeks ]
  • Dietary intake [ Time Frame: 8 weeks ]
  • Hunger and fullness [ Time Frame: 8 weeks ]
  • Lipid profile [ Time Frame: 8 weeks ]
  • Fasting blood glucose [ Time Frame: 8 weeks ]
  • C-reactive protein [ Time Frame: 8 weeks ]
  • Gastrointestinal symptoms and tolerance [ Time Frame: 8 weeks ]
  • Hepatic panel [ Time Frame: 8 weeks ]
  • Serum creatinine [ Time Frame: 8 weeks ]

Estimated Enrollment: 50
Study Start Date: February 2008
Study Completion Date: July 2009
Primary Completion Date: June 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Two 665 mg capsules of glucomannan three times a day for eight weeks
Dietary Supplement: Glucomannan
Two 665 mg capsules of glucomannan three times a day for 8 weeks
Placebo Comparator: 2
Two capsules of inert microcrystalline cellulose three times a day for eight weeks
Dietary Supplement: Inert microcrystalline cellulose
Two capsules of inert microcrystalline cellulose three times a day for eight weeks

Detailed Description:

The primary objective of this exploratory project is to evaluate the safety and efficacy of a highly viscous, water-soluble fiber supplement, glucomannan, for achieving weight loss in overweight and moderately obese individuals. Overweight and obesity are major public health problems in the U.S. that account for substantial morbidity, mortality, and healthcare costs. Conventional approaches to weight loss are largely ineffective, particularly for long-term weight loss and maintenance. Thus, there is a critical need for safe and effective adjunctive treatments. A few, limited studies suggest that glucomannan supplementation is associated with weight loss, is well-tolerated, and has a favorable safety profile.

In this preliminary study, the target population will be overweight and moderately obese individuals, a population that accounts for nearly 50% of all U.S. adults. The specific aims of the project are to: 1) describe the safety of glucomannan for achieving weight loss in overweight and moderately obese individuals, and 2) describe the efficacy of glucomannan for achieving weight loss in overweight and moderately obese individuals. Participants will take glucomannan supplements daily for eight weeks in a double-blind, placebo-controlled, randomized clinical trial. Safety and efficacy outcome measures include: gastrointestinal symptoms/tolerance, hepatic panel, serum creatinine, weight, body composition, diet intake, hunger/fullness, lipid profile, blood glucose, and C-reactive protein. Examination of the safety and efficacy of glucomannan for achieving weight loss will extend our understanding of additional treatments that may be effective in combating a significant public health problem.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • age > or = 18 and < or = 65 years
  • body mass index (BMI) > or = 25 and < or = 35 at study entry
  • speak and understand English (since translated versions of study tools have not been validated)
  • for females only: without childbearing potential or negative HCG hormone blood test and use of an appropriate form of contraception
  • signed informed consent form and HIPAA research authorization

Exclusion Criteria:

  • current use of fiber supplements or intolerance to fiber supplements
  • untreated/unstable metabolic conditions known to influence weight status (e.g., hypothyroidism, type 2 diabetes mellitus)
  • gastrointestinal disorders that might cause complications or influence motility or satiety (e.g., diverticulitis, inflammatory bowel disease, irritable bowel syndrome, intestinal narrowing or obstruction, difficulty swallowing)
  • Stage II hypertension (> or = 160/100 mg Hg) or dyslipidemia (fasting LDL cholesterol > or = 160 mg/dL; total cholesterol > or = 240 mg/dL; triglycerides > 200 mg/dL; HDL < or = 40 mg/dL)
  • fasting serum glucose > 126 mg/dL
  • acute or unstable cardiovascular, pulmonary, hepatic, renal, or psychiatric disorders
  • conditions for which weight loss may not be appropriate (e.g., HIV/AIDS, cancer)
  • use of medications that might affect weight or food absorption (e.g., diuretics, glucocorticoids, anorexigenic agents, Orlistat, laxatives)
  • use of CAM therapies that might affect weight (e.g., acupuncture, Hoodia)
  • weight change of > 5% body weight within 3 months of entry into the study
  • active eating disorders or active participation in a weight loss program
  • renal function impairment as evidenced by a history of renal disease or a serum creatinine > 2.0 mg/dL
  • liver function impairment as evidenced by a history of liver disease or liver enzyme elevations > three times the upper limit of normal (i.e., ALT > 150 u/L and/or AST > 165 u/L)
  • evidence of depression as determined by a weighted score of > or = 16 on the Center for Epidemiological Studies Depression Scale (CES-D), as this may affect eating behavior and adherence to the study protocol
  • currently consumes > or = 10 alcoholic drinks/week, as determined by self-report
  • currently smokes cigarettes due to the effects of nicotine on appetite and C-reactive protein levels
  • use of illicit drugs currently or in the last six months, as determined by self-report
  • for females only: pregnant, less than 6 months postpartum or 6 months post-termination of pregnancy, or currently lactating, due to lack of safety data in this population
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00613600

United States, Illinois
Rush University Medical Center
Chicago, Illinois, United States, 60612
Sponsors and Collaborators
Rush University Medical Center
Principal Investigator: Joyce K Keithley, DNSc, RN Rush University Medical Center
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Joyce K Keithley, Professor, Rush University Medical Center Identifier: NCT00613600     History of Changes
Other Study ID Numbers: RTF-GM
Study First Received: January 31, 2008
Last Updated: December 1, 2011

Keywords provided by Rush University Medical Center:
Dietary fiber
Weight loss

Additional relevant MeSH terms:
Weight Loss
Body Weight
Signs and Symptoms
Body Weight Changes
Gastrointestinal Agents processed this record on April 28, 2017